CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
NET REVENUE
Clinical testing	$ 56,971	$ 52,907
Pharma Services	6,452	4,521
Total Revenue	63,423	57,428
COST OF REVENUE	36,120	34,480
GROSS PROFIT	27,303	22,948
Operating expenses:
General and administrative	17,067	17,018
Research and development	956	862
Sales and marketing	6,775	5,648
Total operating expenses	24,798	23,528
INCOME (LOSS) FROM OPERATIONS	2,505	(580)
Interest expense, net	1,486	1,364
Other income	(63)	0
Income (loss) before taxes	1,082	(1,944)
Income tax (benefit) expense	438	(779)
NET INCOME (LOSS)	644	(1,165)
Deemed dividends on preferred stock	1,003	894
Amortization of preferred stock beneficial conversion feature	1,853	1,672
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (2,212)	$ (3,731)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic (in dollars per share)	$ (0.03)	$ (0.05)
Diluted (in dollars per share)	$ (0.03)	$ (0.05)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	80,507	78,650
Diluted (in shares)	80,507	78,650